logo-loader
viewCEL-SCI Corporation

CelSci updates Phase 3 clinical trial of Advanced Head and Neck Cancer treatment

CEL-SCI Corporation (NYSE:CVM) CEO Geert Kersten sat down with Proactive Investors at the ThinkEquity Conference in New York. The Virginia-based biotech treats patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with its drug Multikine before they receive surgery, radiation and/or chemotherapy.

Quick facts: CEL-SCI Corporation

Price: 12.14 USD

AMEX:CVM
Market: AMEX
Market Cap: $457.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Heat Biologics reveals positive patient survival data from its Phase 2 lung...

Heat Biologics, Inc (NASDAQ:HTBX) Chief Scientific and Operating Officer Jeff Hutchins tells Proactive the North Carolina-based biotech presented positive patient survival data from its Phase 2 lung cancer trial at the American Society of Clinical Oncology annual meeting. Hutchins says Heat's...

34 minutes ago

2 min read